mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Renal cell carcinoma (RCC) typically originates from renal proximal tubules, but current mouse models fail to replicate this origin.
• Understanding RCC pathogenesis is hindered by the limitations of existing animal models in accurately reflecting human disease origins.

Purpose of the Study:

• To investigate the role of mTOR signaling in initiating RCC from renal proximal tubules.
• To elucidate the molecular mechanisms underlying RCC development driven by mTOR activation and associated pathways.

Main Methods:

• Utilized mouse models with targeted ablation of the Tsc1 gene in proximal tubule cells to activate mTOR signaling.
• Investigated the impact of ablating or inhibiting key signaling molecules including MEK1, ERK, MKK6, p38MAPK, p53, and p16.
• Analyzed cyst formation, tumor development, and molecular alterations in genetically modified mice.

Main Results:

• mTOR activation in proximal tubule cells induced precancerous renal cysts.
• MEK1/ERK pathway activation contributed to cyst formation, while its inhibition diminished it.
• Inactivation of p38MAPK, p53, or p16, in conjunction with mTOR activation, promoted renal cell carcinogenesis, leading to clear cell RCC features.

Conclusions:

• mTOR activation, coupled with the inactivation of the p38MAPK-p53/p16 pathway, is a critical driver of RCC development from renal proximal tubules.
• This study identifies novel mechanisms of mTOR-mediated cell proliferation and highlights the MEK-ERK axis as a potential therapeutic target for RCC.
• The findings provide a more accurate mouse model for studying RCC pathogenesis and evaluating potential treatments.